Alvotech Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Alvotech sono diminuiti a un tasso medio annuo di -33.4%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 37.7%.

Informazioni chiave

-33.4%

Tasso di crescita degli utili

86.9%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	37.7%
Rendimento del capitale proprio	n/a
Margine netto	-112.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Alvotech's Position In The Coming Biosimilar Gold Rush

Nov 21

Alvotech: Steady Progress Offers A Good Chance Of Upside

Aug 26

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

Fuji Pharma files for approval of biosimilar candidate in Japan

Oct 17

Alvotech and STADA launch Humira biosimilar in Switzerland

Sep 22

Ripartizione dei ricavi e delle spese

Come Alvotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:ALVO Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	394	-441	62	189
30 Jun 24	309	-618	62	209
31 Mar 24	114	-494	67	191
31 Dec 23	93	-552	74	192
30 Sep 23	64	-596	120	179
30 Jun 23	65	-416	82	175
31 Mar 23	100	-713	101	182
31 Dec 22	85	-514	76	181
30 Sep 22	96	61	51	171
30 Jun 22	78	-12	34	187
31 Mar 22	39	-42	66	190
31 Dec 21	40	-102	68	191
31 Dec 20	69	-170	59	146
31 Dec 19	83	-210	49	96

Guadagni di qualità: ALVO al momento non è redditizia.

Margine di profitto in crescita: ALVO al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ALVO non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 33.4% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ALVO nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ALVO non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: Le passività di ALVO superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Alvotech Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Recent updates

Alvotech's Position In The Coming Biosimilar Gold Rush

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for Avt05, A Proposed Biosimilar to Simponi (Golimumab)

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

Alvotech to Report Q1, 2023 Results on May 18, 2023

Consensus revenue estimates increase by 10%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week